Affimed (AFMDQ)
OTHER OTC:AFMDQ
Top Page
No summary available
Positive Factors
Clinical Progress
Affimed's clinical proof of concept in multiple assets indicates strong potential for future product success, enhancing its competitive position in the immuno-oncology space.
Negative Factors
Revenue Decline
Significant revenue decline indicates challenges in monetizing products, which could impact long-term financial sustainability and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress
Affimed's clinical proof of concept in multiple assets indicates strong potential for future product success, enhancing its competitive position in the immuno-oncology space.
Read all positive factors
Affimed (AFMDQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.04K
Dividend YieldN/A
Average Volume (3M)53.30K
Price to Earnings (P/E)―
Beta (1Y)14.76
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,227,463
10 Day Avg. Volume6,362
30 Day Avg. Volume53,296
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.46
Price to Sales (P/S)10.21
P/FCF Ratio-0.74
Enterprise Value/Market Cap-6.30K
Enterprise Value/Revenue-21.86
Enterprise Value/Gross Profit-21.86
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Affimed Business Overview & Revenue Model
Company Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial ...
How the Company Makes Money
Affimed primarily generates revenue through collaboration and license agreements with pharmaceutical companies, where they develop and commercialize their drug candidates. These agreements often include upfront payments, milestone payments based o...
Affimed Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 877.00K | 8.28M | 41.35M | 40.37M | 28.36M | 21.39M |
| Gross Profit | 877.00K | 8.28M | 41.35M | 40.37M | 28.36M | 21.39M |
| EBITDA | -65.19M | -102.38M | -81.47M | -55.42M | -40.23M | -30.97M |
| Net Income | -69.97M | -105.94M | -86.00M | -57.52M | -41.37M | -32.37M |
Balance Sheet | ||||||
| Total Assets | 39.96M | 97.16M | 200.51M | 225.13M | 175.72M | 112.36M |
| Cash, Cash Equivalents and Short-Term Investments | 24.94M | 72.90M | 190.29M | 197.63M | 146.85M | 104.14M |
| Total Debt | 12.89M | 19.35M | 18.19M | 18.69M | 1.30M | 3.19M |
| Total Liabilities | 22.76M | 39.35M | 47.60M | 89.18M | 103.73M | 73.69M |
| Stockholders Equity | 17.20M | 57.81M | 152.91M | 135.95M | 71.99M | 38.67M |
Cash Flow | ||||||
| Free Cash Flow | -77.44M | -114.00M | -105.59M | -90.44M | -19.84M | -30.53M |
| Operating Cash Flow | -76.90M | -110.27M | -104.89M | -86.59M | -19.40M | -29.06M |
| Investing Cash Flow | 19.68M | -36.06M | 5.61M | -3.85M | 8.01M | 4.34M |
| Financing Cash Flow | 714.00K | -6.22M | 88.56M | 133.58M | 69.25M | 26.04M |
Affimed Technical Analysis
Negative
0.02
Price Trends
0.05
Negative
0.37
Negative
1.17
Negative
Market Momentum
-0.02
Negative
31.31
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AFMDQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 31.31 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AFMDQ.
Affimed Risk Analysis
Affimed disclosed 67 risk factors in its most recent earnings report. Affimed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. Q4, 2023
2.
We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. Q4, 2023
3.
We may submit applications for our product candidates under the Accelerated Approval Program. If we are unable to obtain approval or licensure of our product candidates through the Accelerated Approval Program in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate. Even if we receive approval from the FDA, the FDA may seek to withdraw the approval. Q4, 2023
Affimed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $3.04K | >-0.01 | ― | ― | ― | ― | |
58 Neutral | $29.94M | -3.95 | -61.62% | ― | 4455.07% | 77.31% | |
50 Neutral | $195.14M | 5.44 | -21.16% | ― | -92.42% | 62.37% | |
43 Neutral | $3.32M | -0.15 | -381.74% | ― | ― | 98.22% | |
41 Neutral | $8.65M | -0.31 | -97.58% | ― | -46.88% | 34.83% |
* Healthcare Sector Average
AFMDQ
Affimed
0.02
-0.76
-97.44%
EVAX
Evaxion Biotech
3.59
1.83
103.98%
BOLT
Bolt Biotherapeutics
4.50
-4.00
-47.06%
GRI
GRI Bio
2.30
-119.96
-98.12%
SABS
SAB Biotherapeutics
3.83
2.35
158.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―